Presentation is loading. Please wait.

Presentation is loading. Please wait.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Published byŠtěpán Havlíček Modified over 5 years ago

Similar presentations

Presentation on theme: "Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L"— Presentation transcript:

1 Alefacept in the treatment of psoriatic nail disease: A small case series 
Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L. Shupack, MD, Bruce E. Strober, MD, PhD  Journal of the American Academy of Dermatology  Volume 52, Issue 6, Pages (June 2005) DOI: /j.jaad Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 A and B. Patient B. Psoriatic nail at baseline (A) and week 6 follow-up (B) visits. C and D, Patient E. Psoriatic nail at baseline (C) and week 6 follow-up (D) visits. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L"

Similar presentations

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Analysis of US dermatology physician assistant density

Analysis of US dermatology physician assistant density
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Analysis of US dermatology physician assistant density

Analysis of US dermatology physician assistant density
A girl with a solitary red bulla

A girl with a solitary red bulla
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 
Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Pediatric teledermatology: Observations based on 429 consults

Pediatric teledermatology: Observations based on 429 consults
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
JAK inhibitors in dermatology: The promise of a new drug class

JAK inhibitors in dermatology: The promise of a new drug class
Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Similar presentations

Ads by Google